** Shares of Sun Pharma SUN.NS down 0.7% to 1,876.9 rupees ahead of its quarterly earnings; Nifty pharma .NIPHARM down 0.6%
** Analysts, on average expect drugmaker to post 31.3% rise in Q4 net profit at 28.22 billion rupees ($293.8 million) - LSEG-compiled data
** Jefferies projects 14% year-over-year growth in domestic business, driven by strong adoption of chronic therapies
** Brokerage warns of potential sequential decline in U.S. sales due to lower generic Revlimid revenues
** HSBC anticipates a strong quarter, supported by India operations and innovative medicines segment; expects SUN to post mid-single digit to mid-teens YoY growth in India sales but flags possible sequential decline in innovative medicines
** Stock rated as "Buy" on average by 31 analysts; median PT at 1,990 rupees - data compiled by LSEG
** YTD, stock up 9.7% vs Nifty pharma's rise of 8.8%
($1 = 96.0425 Indian rupees)
(Reporting by Mridula Kumar in Bengaluru)
((Mridula.Kumar@thomsonreuters.com;))